Until the early 1980s, protein degradation was a neglected research area, and scientists were mostly busy deciphering the genetic code and its translation to the proteome. Destruction of cellular proteins was thought to be a scavenger, non-specific and dead-end process. Although it was known that proteins do turn over, the large extent and high specificity of the process, whereby distinct proteins have half-lives that range from a few minutes to several days, was not appreciated. The discovery of the lysosome by Christian de Duve did not change this view significantly, as it was clear that this organelle is involved mostly in the degradation of extracellular proteins, and their proteases cannot be substrate-specific. The discovery of the complex cascade of the ubiquitin pathway revolutionized the field. It is clear now that degradation of cellular proteins via the ubiquitin system is a highly complex, temporally controlled and tightly regulated process that plays major roles in a variety of basic pathways and processes during cell life and death, and in health and disease. The system is involved in targeting many cellular proteins, among them cell cycle regulators, growthand differentiation-controlling factors, transcriptional activators, cell-surface receptors and ion channels, endoplasmic reticulum proteins, antigenic proteins destined for presentation on class I MHC molecules, and abnormal/misfolded proteins. Consequently, it is involved in regulating many basic cellular processes, such as cell cycle and division, growth and differentiation, signal transduction and transcription, modulation of the secretory and endocytic pathways, the immune and inflammatory responses, and quality control. With the multitude of substrates targeted and the numerous processes involved, it is not surprising that aberrations in the pathway have been implicated in the pathogenesis of many diseases, with certain malignancies and neurodegenerative disorders being ranked among them.
Introduction
Degradation of a protein via the ubiquitin-proteasome pathway involves two discrete and successive steps: (i) tagging of the substrate by covalent attachment of multiple ubiquitin molecules; and (ii) degradation of the tagged protein by the 26 S proteasome complex with release of free and reutilizable ubiquitin. This last process is mediated by ubiquitin-recycling enzymes (deubiquitinating enzymes, or 'DUBs'). Conjugation of ubiquitin, a highly evolutionarily conserved 76-residue polypeptide, to the protein substrate proceeds via a three-step cascade mechanism. Initially, the ubiquitin-activating enzyme, E1, activates ubiquitin in an ATP-requiring reaction to generate a high-energy thiol-ester intermediate, E1-S∼ubiquitin. One of several E2 enzymes [ubiquitin-carrier proteins or ubiquitin-conjugating enzymes ('UBCs')] transfers the activated ubiquitin moiety from E1, via an additional high-energy thiol-ester intermediate, E2-S∼ubiquitin, to the substrate that is specifically bound to a member of the ubiquitin-protein ligase family, E3. There are a number of different classes of E3 enzymes. For the HECT (homologous with the E6-AP C-terminus)-domain E3s, the ubiquitin is transferred once again from the E2 enzyme to an active site cysteine residue on E3, to generate a third high-energy thiol-ester intermediate, E3-S∼ubiquitin, prior to its transfer to the ligase-bound substrate. RING finger containing E3s catalyse direct transfer of the activated ubiquitin moiety to the E3-bound substrate. E3s catalyse the last step in the conjugation process: covalent attachment of ubiquitin to the substrate. The ubiquitin molecule is generally transferred to an ε-NH 2 group of an internal lysine residue in the substrate to generate a covalent isopeptide bond. By successively adding activated ubiquitin moieties to internal lysine residues on the previously conjugated ubiquitin molecule, a polyubiquitin chain is synthesized. The chain is recognized by the downstream 26 S proteasome complex. Thus E3s play a key role in the ubiquitin-mediated proteolytic cascade, since they serve as the specific recognition factors of the system. The 26 S proteasome is a large multicatalytic protease that degrades polyubiquitinated proteins to small peptides. It is composed of two subcomplexes: a 20 S core particle (CP) that carries the catalytic activity, and a regulatory 19 S regulatory particle (RP). The 20 S CP is a barrel-shaped structure composed of four stacked rings, two identical outer α rings and two identical inner β rings. The eukaryotic α and β rings are composed each of seven distinct subunits, giving the 20 S complex the general structure of α 1−7 β 1−7 β 1−7 α 1−7 . The catalytic sites are localized to some of the β subunits. Each extremity of the 20 S barrel can be capped by a 19 S RP. One important function of the 19 S RP is to recognize ubiquitinated proteins and other potential substrates of the proteasome. A ubiquitin-binding subunit of the 19 S RP has indeed been identified; however, its importance and mode of action have not been discerned. A second function of the 19 S RP is to open an orifice in the α ring that will allow entry of the substrate into the proteolytic chamber. Also, since a folded protein would not be able to fit through the narrow proteasomal channel, it is assumed that the 19 S particle unfolds substrates and assists in inserting them into the 20 S CP. Both the channel-opening function and the unfolding of the substrate require metabolic energy and, indeed, the 19 S RP contains six different ATPase subunits. Following degradation of the substrate, short peptides derived from the substrate are released, as well as reutilizable ubiquitin (for a general scheme of the ubiquitin system, see Figure 1 ).
A major unresolved question concerns how the system achieves its high specificity and selectivity. Why are certain proteins extremely stable in the cell, whereas others are extremely short-lived? Why are certain proteins degraded only at a particular time point during the cell cycle or only following specific extracellular stimuli, yet they are stable under most other conditions? It appears that specificity of the ubiquitin system is determined by two distinct and unrelated groups of proteins: E3s and ancillary proteins. First, within the ubiquitin system, substrates must be specifically recognized by an appropriate E3 as a prerequisite to their ubiquitination. In most cases, however, substrates are not recognized in a constitutive manner and, in some cases, they are not recognized directly by the E3. In many cases, the substrate must undergo a certain change that renders it susceptible for recognition. In some instances, the E3 must 'be switched on' by undergoing post-translational modification in order to yield an active form that recognizes the substrate. The stability of additional proteins depends on association with ancillary proteins, such as molecular chaperones that act as recognition elements in trans and serve as a link to the appropriate ligase. Others, such as certain transcription factors, have to dissociate from the specific DNA sequence to which they bind in order to be recognized by the system. Stability of yet other proteins depends on oligomerization. Thus, in addition to the E3s themselves, modifying enzymes (such as kinases), ancillary proteins, or DNA sequences to which substrates bind also play an important role in the recognition process.
Ubiquitin-mediated proteolysis of a variety of cellular proteins plays an important role in many basic cellular processes. Among these are regulation of cell cycle and division, differentiation and development, involvement in the cellular response to stress and extracellular effectors, morphogenesis of neuronal networks, modulation of cell-surface receptors, ion channels and the secretory pathway, DNA repair, transcriptional regulation, transcriptional silencing, longterm memory, circadian rhythms, regulation of the immune and inflammatory responses, and biogenesis of organelles. The list of cellular proteins that are targeted by ubiquitin is growing rapidly. Among them are cell cycle regulators, such as cyclins, cyclin-dependent kinase (CDK) inhibitors and proteins involved in sister chromatid separation, tumour suppressors, transcriptional activators and their inhibitors. Cell-surface receptors and endoplasmic reticulum (ER) proteins are also targeted by the system. Finally, mutated and denatured/misfolded proteins are recognized specifically, and are removed efficiently. In this capacity, the system is a key player in the cellular quality control and defence mechanisms (for selected recent review articles and a monograph on the ubiquitin-proteasome pathway, see refs. [1] [2] [3] [4] [5] ).
With the many substrates targeted and processes involved, it is not surprising to find that aberrations in the ubiquitin system underlie the pathogenesis of many diseases. Whereas inactivation of a major enzyme, such as E1, is obviously lethal, mutations in enzymes or in recognition motifs in substrates that do not affect vital pathways, or that affect the involved process only partially, result in a broad array of phenotypes. Likewise, acquired changes in the activity of the system can also evolve into certain pathologies. The pathological states associated with the ubiquitin system can be classified into two groups: (i) those that result from loss of function, i.e. mutations in a ubiquitin-system enzyme or target substrate that result in stabilization of certain proteins; and (ii) those that result from gain of function, i.e. abnormal or accelerated degradation of the protein target.
Ubiquitination in the pathogenesis of human diseases

Malignancies
Alterations in ubiquitination and deubiquitination reactions have been directly implicated in the aetiology of many malignancies. In general, specific cancers can result from stabilization of oncoproteins, or destabilization of tumour suppressor genes. Some of the natural substrates for degradation by the proteasome are oncoproteins that, if not properly removed from the cell, can promote cancer. For instance, the ubiquitin system targets NMyc, c-Myc, c-Fos, c-Jun, Src and the adenovirus E1A proteins. Aberrations in their removal may derail the cell cycle and result in malignant transformation. Likewise, destabilization of tumour suppressor proteins, such as p53 and p27, has also been implicated in the pathogenesis of malignancies. It was noted that the level of the tumour suppressor protein p53 is extremely low in uterine cervical carcinoma tumours caused by high-risk strains of the human papillomavirus (HPV). Detailed studies have shown that the suppressor is targeted for ubiquitin-mediated degradation by the HPV oncoprotein E6 encoded by high-risk species of the virus (E6-16 or -18, for example; [6] ). Degradation is mediated by the HECT domain E3 enzyme E6-AP, where E6 serves as an ancillary protein that allows recognition in trans. Removal of the suppressor by the oncoprotein is probably an important mechanism used by the virus to transform cells.
Likewise, low levels of the CDK inhibitor of the cell cycle, p27 Kip1 , which result from increased ubiquitin-mediated degradation, have been demonstrated in many colorectal, prostate and breast cancers [7] . The protein acts as a negative growth regulator/tumour suppressor and plays an important role in proliferation of mammalian cells. It binds and negatively regulates the activity of CDK2-cyclin E and CDK2-cyclin A complexes, and thus does not allow cell cycle progression from G 1 and entrance into the S-phase. Its level is high in quiescent cells but, following mitogenic stimuli, it is rapidly degraded by the ubiquitin system, allowing the CDK-cyclin complexes to drive the cell into the S-phase. In many of the malignancies, there was a strong correlation between the low level of p27 and the aggressiveness of the disease, i.e. tumour grading, clinical staging and poor prognosis of the patients. Consequently, levels of p27 have become an important prognostic factor for survival, recurrence and evaluation of therapy [8] . Dissection of the mechanism that underlies the decrease in p27 revealed that, unlike the case of other tumour suppressors like p53, which are mutated and stabilized in many tumours, the rapidly degraded p27 is of the wild-type (WT) species, and it is probably abnormal activation of the ubiquitin system that leads to accelerated degradation of the suppressor. Mechanistic analysis revealed that the low levels of p27 correlate directly with an increased level of Skp2, the F-box protein involved in p27 ubiquitination, and that ectopic overexpression of Skp2 in experimental animals is oncogenic [9] .
β-Catenin plays an important role in signal transduction and differentiation of the colorectal epithelium, and aberrations in ubiquitin-mediated regulation of its levels may be important in the multi-step development of colorectal tumours [10] . In the absence of signalling, glycogen synthase kinase 3β (GSK3β) is active and phosphorylates β-catenin, which is then degraded via the ubiquitin-proteasome pathway [11] . Cell signalling promotes dephosphorylation, stabilization and subsequent activation of β-catenin via complex formation with T-cell factor ('TCF') and lymphocyte enhancer factor-1 ('LEF-1'), which are otherwise inactive subunits of transcription factor complexes. β-Catenin interacts with the 300 kDa tumour suppressor APC (adenomatous polyposis coli), which appears to regulate, in an as-yet-unknown manner, its intracellular level. Aberrations in degradation of β-catenin lead to its stabilization, accumulation and subsequent oncogenic activation, and can result from two distinct mechanisms: (i) mutations in the phosphorylation recognition motif of the β-catenin protein; and (ii) mutations in the targeting machinery of β-catenin. Mutations in β-catenin in which target residues of GSK3β that undergo phosphorylation are substituted with amino acids that cannot be modified stabilize the protein, and have been described in several colorectal carcinomas and also in malignant melanomas. Furthermore, in colon cancer cells that do not express APC or that harbour APC proteins that are mutated in one of the catenin binding clusters, β-catenin accumulates in the cytosol and is translocated into the nucleus, where it acts as part of an active transcriptional complex. Expression of full-length APC in these cells leads to degradation of excess β-catenin and to abrogation of the transactivation effect.
Mutations in one germ line copy of the von Hippel Lindau protein (pVHL) predisposes individuals to a wide range of malignancies, including renal cell carcinoma, phaeochromocytoma, cerebellar haemangioblastomas and retinal angiomas. A hallmark of VHL −/− tumours is a high degree of vascularization, which arises from constitutive expression of hypoxia-inducible genes, including the master switch transcription factor hypoxia-inducible factor α (HIF-α) and the crucial vascular endothelial growth factor ('VEGF'). It has been recently shown that pVHL is a ubiquitin ligase that is involved in targeting of HIF-α for ubiquitinand proteasome-mediated degradation following specific recognition of an oxygen-induced, hydroxylated proline residue. It is possible that the high, non-regulated activity of HIF-α, and possibly other targets of pVHL, underlie the high frequency of malignant transformations observed in carriers of mutations in pVHL (reviewed recently in [12] ).
Fanconi anaemia (FA) is an autosomal recessive disease characterized by congenital abnormalities, progressive bonemarrow failure, cellular sensitivity to DNA cross-linking agents and cancer susceptibility. Normally, several FA proteins, including proteins A, C, E, F and G, generate a complex that attaches a single ubiquitin moiety to FA D2 on Lys 562 . This enables FA D2 to translocate to nuclear DNArepair foci where, along with breast-cancer susceptibility gene (BRCA) 1, BRCA2, FA D1 and RAD51, it is involved in homology-directed DNA repair. Mutations in any of the proteins involved in these pathway, including those participating in the mono-ubiquitiating machinery, have been described in different FA patients [13] .
Liddle's syndrome
An interesting syndrome involves aberration in the regulation of kidney epithelial Na + channel. This channel, which is a cell-surface-membrane heterotrimeric protein, is shortlived, and is both degraded by the ubiquitin system and recognized via a proline-rich (PY) motif by NEDD4, a HECT-domain-containing E3 [14] . A mutation in the PY motif leads to stabilization of the channel complex (because it does not associate any more with the ligase), accumulation of its subunits, excessive reabsorption of Na + and H 2 O, and, consequently, a severe form of early onset hypertension.
Angelman syndrome
A defect in the gene coding for the E3 ligase E6-AP (see above) has been implicated as the cause of Angelman syndrome, which is characterized by mental retardation, seizures, out-of-context frequent smiling and laughter, and abnormal gait [15] . The target brain protein(s), which are most probably stabilized and accumulated because of the mutation, have not been identified. However, unlike in E6-mediated targeting of p53 (see above), the degradation of this putative protein(s) is E6-independent, and it is probably one of the native substrates of E6-AP. Interestingly, the disease displays genomic imprinting, where a subset of mammalian genes can be expressed monoallelically in a parent-of-origin manner (uniparental disomy; 'UPD'). In the case of Angelman syndrome, the imprinted gene is localized to chromosome 15q11-q13, where deletions in the disease were identified.
Neurodegenerative diseases
Accumulation of ubiquitin conjugates and/or inclusion bodies associated with ubiquitin, proteasomal and certain disease-characteristic proteins has been reported in a broad array of chronic neurodegenerative diseases. The neurofibrillary tangles of Alzheimer's disease (AD), brainstem Lewy bodies (LBs) -the neuropathological hallmark in Parkinson's disease (PD) -Bunina bodies in amyotrophic lateral sclerosis ('ALS'), and nuclear inclusions in CAGrepeat expansion (polyglutamine extension) disorders, such as Huntington's disease (HD), spinocerebellar ataxias (SCAs) and spinobulbar muscular atrophy (Kennedy's syndrome), have all been reported to contain elements of the ubiquitin system [16] . However, in all these cases, a direct pathogenetic linkage to aberrations in the ubiquitin system has not been established. One factor that complicates the establishment of such a linkage is the realization that many of these diseases, such as Alzheimer's and Parkinson's, are not defined clinical entities, but rather syndromes with different aetiologies. Accumulation of ubiquitin conjugates in inclusion LBs in many of these cases may be secondary, and reflect unsuccessful attempts by the ubiquitination and proteasomal machineries to remove damaged/abnormal proteins. Although the initial hypothesis was that inclusion LBs are generated because of the inherent tendency of the abnormal proteins to associate with one another and aggregate, it is now thought that the process may be more complex and involves active cellular machineries, including inhibition of the ubiquitin system by the aggregated proteins [17] .
The case of PD highlights the complexity of the involvement of the ubiquitin system in the pathogenesis of neurodegeneration. Recent evidence has implicated mutations in α-synuclein in the pathogenesis of neurodegeneration. Initially, it was identified in several cases of autosomal dominant familial PD. Later, the protein was shown to be a major component of LBs and Lewy neurites in sporadic PD, dementia with LBs ('DLB'), and the LB variant of AD. The function of α-synuclein is not known. Furthermore, although it has been shown that the protein is targeted by the proteasome, it is not known whether the mutations affect its stability and lead to its accumulation and the resulting toxicity. Moreover, although LBs contain α-synuclein and ubiquitin, it is not clear that it is the conjugated form of synuclein that is accumulated [18] . In a different case, recent findings in a German family with PD have revealed mutations in the gene encoding the ubiquitin-recycling isoenzyme, ubiquitin C-terminal hydrolase (UCH-L1) [19] . The hypothesis here is that the mutation results in a shortage of free ubiquitin required for degradation of certain as-yetunidentified proteins that, when they accumulate, are toxic to neurons. Interestingly, mutations in UCH-L1 lead to gracile axonal dystrophy (GAD syndrome) in mice. This is a recessive autosomal mutation that displays sensory ataxia at an early stage, followed by motor ataxia at a later stage. A third player in the pathogenesis of PD is Parkin. Parkin is a RING-finger-containing E3 protein.
Mutations in the gene appear to be responsible for the pathogenesis of autosomal recessive juvenile Parkinsonism (AR-JP), one of the most common familial forms of PD [20] . Interestingly, this disease is characterized by a lack of LBs, the pathognomonic hallmark of sporadic forms of the disease. Parkin ubiquitinates and promotes degradation of several proteins, among which are CDCrel-1, a synaptic vesicleenriched septin GTPase implicated in the inhibition of exocytosis through its interactions with syntaxin, synphilin-1, an α-synuclein-associated protein that is also involved in generation of nuclear inclusions, and the Pael receptor, a putative G-protein-coupled transmembrane polypeptide that, when overexpressed in cells, tends to become unfolded and insoluble. The insoluble Pael receptor leads to unfolded protein-induced cell death. Whether aberrations in the degradation of these substrates or of other as-yet-unidentified substrate(s) of Parkin underlies the pathogenesis of AR-JP is not known. Nevertheless, the discovery of Parkin, its general function and its mutations in Parkinson's disease are of utmost importance, since these findings point clearly towards a direct aetiological role of this enzyme.
AD is also characterized by accumulation/association of ubiquitin with Tau in neurofibrillary tangles and senile plaques, both characteristic of the neuronal abnormalities associated with the disease. They are also present in LBs that are characteristic of some forms of the diseases. However, in all these cases, the role of Tau and other putative target proteins in the pathogenesis of the disease are still not known. A more direct relationship between the ubiquitin system and pathogenesis of AD was established with the discovery of a frameshift mutation in the ubiquitin transcript, which leads to an extension of the molecule by 20 amino acid residues [Ub(+1)], and which has been selectively observed in brains of AD patients, including those with late-onset, non-familial disease [20] . Ub(+1) is an efficient substrate for polyubiquitination; however, the resulting polyubiquitin chains are refractory to disassembly by deubiquitinating enzymes and potently inhibit the degradation of a polyubiquitinated substrate by the 26 S proteasome [21] . Thus expression of Ub(+1) in the brain could potentially result in dominant inhibition of the ubiquitin-proteasome system, leading to accumulation of toxic proteins with neuropathological consequences. Additional, and probably distinct, players in the pathogenesis of AD are the presenilins (PSs) 1 and 2, which are involved in processing of the amyloid precursor protein (APP). Numerous mutations causing earlyonset AD have been identified in the PS genes, particularly the PS1 gene. Both PS1 and PS2 are targeted by the ubiquitin system. It is not clear whether, here, aberrations in the degradation of the mutant proteins play any role in the pathogenetic process, or whether it is an aberration in the function of the PSs in the processing of APP (which may not be related to the function of the ubiquitin system) that underlies the pathology observed in AD.
Another group of genetically inherited neurodegenerative disorders is caused by a genomic instability that leads to an expanded 5 -CAG repeat, which is translated to an N-terminal polyglutamine repeat extension. In the case of HD, the affected gene is Huntingtin, which codes for a protein of unknown function. In another series of diseases, spinocerebellar ataxias (SCAs 1-3) , the affected proteins are ataxins 1-3 respectively, and in spinobulbar muscular atrophy, the affected protein is the androgen receptor. The polyglutamine-containing proteins aggregate and accumulate in intranuclear inclusion bodies, which are stained also for ubiquitin that is probably attached to them. Huntingtin and ataxin 1 are probably targeted by the ubiquitin system. Furthermore, at least for ataxin 1, it has been shown that the degradation of the polyglutamine-containing and mutated protein in vitro is somewhat slower than that of the WT protein [22] , suggesting that the inability of the system to remove the mutated protein may underlie its accumulation and possible aggregation. Although it is clear that the known catalytic sites of the proteasome cannot cleave within the polyglutamine repeat, it is not known whether the aberration leads to accumulation of the intact proteins, or of long polyglutamine stretches that are released from them. Also, it is not clear whether the aggregated protein and/or the inclusion bodies are toxic; initial experimental evidence suggests that the inclusion bodies may serve as an alternative scavenger mechanism to store proteins that cannot be removed by the ubiquitin system, and that 'solubilization' of these proteins via expression of chaperones, for example, aggravates the disease symptoms [22] .
Cystic fibrosis (CF)
The CF gene encodes the CF transmembrane regulator (CFTR), which is a 1480-amino-acid-residues-long chloride ion channel. Only a small fraction of the WT protein matures to the cell surface, whereas most of the protein is degraded from within the ER by the ubiquitin system. Although more than 600 mutations have been described, the most frequent one (>70%) is Phe 508 . The mutation leads to an autosomal recessive inherited multisystem disorder characterized by chronic obstruction of airways and severe maldigestion due to exocrine pancreatic dysfunction. Despite normal ion-channel function, CFTR F508 does not reach the cell surface at all, as it is rapidly degraded. Chemical and pharmacological chaperones and drugs that interfere with proteasomal degradation have the potential to alter the kinetics of trafficking, allowing even mutated CFTR molecules to reach the cell surface and function there [23] .
Immune and inflammatory response As described above, the HPV evolved a mechanism for proteolytic removal of p53 that enables continuous replication and propagation of the virus under conditions of DNA damage that normally would have resulted in p53-induced apoptosis. Two other viruses evolved mechanisms that also utilize the ubiquitin system, here to escape immune surveillance. One case is that of the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1), which persists in healthy virus carriers for life, and is the only viral protein regularly detected in all EBV-associated malignancies, such as Burkitt's lymphoma. Unlike EBNAs 2-4, which are strong immunogens, EBNA1 is not processed and cannot elicit a cytotoxic T-lymphocyte (CTL) response. The persistence of EBNA1 contributes, most probably, to some of the pathologies caused by the virus. An interesting structural feature common to all EBNA1 proteins derived from different EBV strains is a relatively long and unusual Gly-Ala repeat at the N-terminal domain of the molecule. Transfer of a strong antigenic epitope from EBNA4 to EBNA1 prevented its presentation, whereas its insertion into an EBNA1 mutant that lacks the Gly-Ala repeat results in its presentation to the appropriate CTL. Similarly, insertion of the Gly-Ala repeat to EBNA4 inhibited CTL recognition of EBNA4-derived antigenic peptides. Thus the Gly-Ala repeat constitutes a cis-acting element that inhibits antigen processing and subsequent presentation of potential antigenic epitopes. It has been shown that whereas EBNA4, like many other known MHC class I antigens, is degraded in an ATP-, ubiquitin-and proteasome-dependent manner, EBNA1 is resistant to proteolysis. EBNA1 will become susceptible to degradation, however, if the Gly-Ala repeat is deleted [24] . Thus the evolution of the Gly-Ala repeat enabled the virus to evade proteolysis and subsequent presentation to the immune system. An additional interesting case involves the pathobiology of the human cytomegalovirus ('CMV'). The virus encodes two ER-resident proteins, US2 and US11, that down-regulate the MHC class I heavy chain antigenic peptide carriers. MHC molecules are synthesized and transported to the ER (where they are glycosylated), but, shortly thereafter, in cells expressing US2 or US11, are transported back to the cytosol, deglycosylated and degraded by the proteasome following ubiquitination [25] . The viral products bind to the MHC molecules and relocate them to the translocation machinery, where they are transported back into the cytosol. The mechanism of action of the viral proteins is not known. They may diffuse laterally in the membrane and interact with the emerging nascent MHC chain, an interaction that does not allow insertion of the stop-transfer signal and proper anchoring and folding of the molecule in the membrane. Alternatively, they may compete with the binding of the ER chaperones, which may be necessary for proper folding of the MHC molecule. In both cases, the misfolded or otherwise 'abnormal' proteins are subjected to destruction via the ER-associated degradation machinery ('ERAD') that has an important role in the cellular quality control mechanism, the removal of the MHC molecules does not allow presentation of the viral antigenic peptides, thus enabling the virus to evade the immune system.
Thus it appears that evolution of many viruses has involved intimate recognition with a variety of proteolytic processes. This has enabled the development of viral mechanisms that enhance the function of the viral replication and propagation machineries via subversion of the normal cellular proteolytic pathways.
Muscle wasting
The ubiquitin system plays major roles in pathophysiological processes in the muscle. Muscle degeneration, which follows long-term immobilization, denervation and severe catabolic states, such as occurs in sepsis and cancer-induced cachexia, leads to activation of the ubiquitin pathway and induction of many of its enzymic components. This, in turn, results in massive degradation of muscle proteins [26] . The nature of signalling mechanisms is still obscure, and it appears that cytokines such as tumour necrosis factor α ('TNFα') and interleukin-6 (IL-6) are not involved, at least not directly. Two recently described muscle-specific and degenerationinducible ubiquitin ligases have been identified, and yet both their substrates and mode of action are still unknown [27] .
Drug development for targeting aberrant activity of the ubiquitin system
Because of the central role the ubiquitin system has in a broad array of basic cellular processes, development of drugs that modulate the activity of the system may be difficult. Inhibition of enzymes common to the entire pathway, such as the proteasome, may affect many processes non-specifically, although a narrow window between beneficial effects and toxicity can be identified for a short-term treatment. Recent experimental evidence strongly suggests that such inhibitors may indeed be beneficial in certain pathologies, such as in cancer, asthma, brain infarct and autoimmune encephalomyelitis. In malignancies, the drugs may act via inhibition of activation of the anti-apoptotic transcriptional regulator nuclear factor κB (NF-κB), thus sensitizing cells to irradiation and chemotherapy-induced apoptosis. The inhibitors may also act via inhibition of degradation of different cell cycle regulators. In neuroprotection, they may also act via inhibiting activation of NF-κB, thus suppressing the local inflammatory response. In autoimmune diseases, they may act by inhibiting presentation of 'self' peptides, and also by interfering with signal transduction along cellular immune cascades (on the development of proteasome inhibitors as drugs, and in particular, on their potential in cancer therapy, see [28] ). A completely different approach to drug development can be the development of small molecules that bind and inhibit specific E3s. For example, specific phosphopeptide derivatives that span the phosphorylation-targeting domains in different substrates can serve as 'baits' to the respective E3s [29] . This approach can turn, however, into a 'double-edged sword'. In the case of inhibitory κB (IκB) α, where phosphorylation destabilizes a negative regulator, inhibition of the βTrCP E3 protein can stabilize the protein and decrease the untoward activity of the immune system and its resulting inflammatory response. However, the similarity between the phosphorylation sites of IκBα and β-catenin may lead also to stabilization of β-catenin, which is an activator, and its excessive transcriptional activity can result in malignant transformation (see above). A better approach may be the development of small molecules that are substrate-specific and bind, preferably, to specific substrates or to their ancillary proteins, rather than to an E3 protein. When accelerated degradation of a tumour suppressor results in exposure of cells to malignant transformation, selective inhibition of the recognition machinery can potentially reverse the malignant phenotype. Peptides that bind specifically to HPV-E6 and prevent its association with p53 interfere with p53 targeting. They were able to induce p53 in HPV-transformed cells with subsequent reversal of certain malignant characteristics or induction of apoptosis [30] . Treatment directed at increasing the level of the CDK inhibitor p27
Kip1 resulted in regression of the malignant phenotype in experimental models. While it is not clear that they act via the ubiquitin system, IL-6 and phenylacetate, for example, lead to G 1 arrest by increasing the level of p27.
